वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
Insulet Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $9.3B | |
|---|---|---|
| P/E (forward) | 55.0x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $1.04B | $1.06B | $1.70B | $2.07B | $2.71B | +27.0% |
| Gross profit | $752.1M | $805.6M | $1.16B | $1.45B | $1.94B | +26.7% |
| Operating income | $126.0M | $37.6M | $220.1M | $308.9M | $473.8M | +39.3% |
| Net income | $16.8M | $4.6M | $206.3M | $418.3M | $247.1M | +95.8% |
| EPS (diluted) | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 | +95.1% |
| EBITDA | $139.6M | $109.0M | $323.6M | $423.7M | $509.6M | +38.2% |
| R&D | $160.1M | $180.2M | $205.0M | $219.6M | $301.1M | +17.1% |
| SG&A | $466.0M | $587.8M | $734.8M | $917.2M | $1.17B | +25.7% |
Recent company headlines from major financial publishers.
The modal expected path reflects consensus-aligned execution: FY2026 revenue of $3,287.08M (21.38% growth) and FY2027 revenue of $3,735.00M (13.63% growth), guided by mid-teens exit growth. Operating margins expand ~100 basis points annually from 17.5% in FY2025 to 22.5% by FY2030, supporting diluted EPS of $6.51 in FY2026 and $7.73 in FY2027, yielding our house Fair value of $164.82.
Accelerated adoption of Omnipod 5 across intensive and basal Type 2 diabetes segments combines with rapid international expansion, driving consolidated top-line growth above 25% annually. Automated manufacturing lines achieve optimal yield efficiencies, expanding operating margins beyond 24% and compounding diluted EPS above 25% annually toward our high-case valuation of $210.43,.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 8.5% | $171 | $177 | $184 | $193 | $203 |
| 9.0% | $163 | $168 | $174 | $181 | $189 |
| 9.5% | $156 | $160 | $165 | $171 | $177 |
| 10.0% | $149 | $153 | $157 | $162 | $168 |
| 10.5% | $143 | $147 | $150 | $154 | $159 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |